Klaus Wolff

Title: Klaus Wolff: Innovator in Human Endogenous Retrovirus Research

Introduction

Klaus Wolff is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of biotechnology, particularly in the study of human endogenous retroviruses. With a total of 2 patents, his work has implications for understanding infectious diseases and developing potential therapeutic approaches.

Latest Patents

Wolff's latest patents focus on polynucleotide fragments of an infectious human endogenous retrovirus. One patent describes nucleotide sequences and fragments that code for a human endogenous retrovirus, which is infectious. These fragments are related to specific sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt, and MERV-pol. The invention also contemplates methods of using these sequences, polypeptides encoded by them, antibodies directed against these sequences, and related methods and compositions. Another patent details a polynucleotide molecule that is a fragment of a polynucleotide sequence of an infectious human endogenous retrovirus. This molecule comprises sequences with high identity to a specific sequence, as well as variations due to the degeneration of the genetic code.

Career Highlights

Klaus Wolff is associated with Avir Green Hills Biotechnology Research Development Trade AG, where he continues to advance research in his field. His work has been instrumental in exploring the complexities of human endogenous retroviruses and their potential impact on human health.

Collaborations

Wolff has collaborated with notable colleagues such as Hubert Pehamberger and Andreas Grassauer. These partnerships have contributed to the depth and breadth of his research endeavors.

Conclusion

Klaus Wolff's innovative work in the field of human endogenous retroviruses highlights his role as a key inventor in biotechnology. His patents reflect a commitment to advancing scientific knowledge and potential therapeutic applications.